This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering

Strategies to Innovate the Production of Next Generation Bioconjugates

Posted by on 26 June 2020
Share this article

From ADC development to tumor-targeting, there are still many lessons to be learned in the world of conjugation.

This whitepaper reviews the latest common challenges and novel strategies for accelerating bioconjugates, across preclinical, research & development and CMC considerations.

It includes:

  • Antibody, site, linker & payload combinations to optimize ADCs
  • Improved targeting for solid tumors
  • Novel payloads and delivery vehicles including antibody fragment–drug, centyrin, peptide drug and oligonucleotide conjugates

Click on the image below or here to explore the whitepaper. 

Have any questions about the report or interested in sponsoring a future whitepaper? Email

Share this article